“ARCA started because there was a heartbreaking need for new drugs to treat HIV,” says Melanie Thompson, M.D. “The landscape for HIV research has indeed changed, largely as a result of our successes.”
U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.
In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.
Most people living with HIV will never need fostemsavir. But for those who do, the drug can be a life-saver—and that is pretty epic.
Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.
Taken together, these studies appear to confirm that weight gain is a class effect of INSTIs, albeit with potential differences between individual drugs—and much left to be learned about the health impact.
Although the mechanism and long-term implications remain unclear, these studies affirm that the effect is occurring—and that a person’s prior HIV treatment regimen may play a role.
B/F/TAF Holds Up as Switch Regimen for Black People Living With HIV, Including Those With Resistance
While the most striking aspect of the study was its demographic focus, the baseline resistance profile of the participants was also key.
To Increase Access to HIV Post-Exposure Prophylaxis, New York State Updated Its Guidelines for Clinicians
If you’re a provider in or outside the state, you’ll want to read these new guidelines.
Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.